Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China

Dual therapy with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) has been demonstrated to be non-inferior to the triple drug regimen including LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) in 48-week studies. However, little is known about the long-term efficacy and drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Peng-Le, He, Hao-Lan, Chen, Xie-Jie, Chen, Jin-Feng, Chen, Xiao-Ting, Lan, Yun, Wang, Jian, Du, Pei-Shan, Zhong, Huo-Lin, Li, Hong, Liu, Cong, Li, Li-Ya, Hu, Feng-Yu, Tang, Xiao-Ping, Cai, Wei-Ping, Li, Ling-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027496/
https://www.ncbi.nlm.nih.gov/pubmed/33841131
http://dx.doi.org/10.3389/fphar.2020.569766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027496/
https://www.ncbi.nlm.nih.gov/pubmed/33841131
http://dx.doi.org/10.3389/fphar.2020.569766

Ejemplares similares